CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
TiME 之问：微环境相互作用如何塑造 CLL 与 Richter 转化的免疫治疗应答
英文原题：A question of TiME: how microenvironmental interactions shape response to immunotherapy in CLL and Richter Transformation.
查看英文原题
A question of TiME: how microenvironmental interactions shape response to immunotherapy in CLL and Richter Transformation.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
免疫治疗已经彻底改变了许多癌症的治疗格局，包括一些B细胞淋巴瘤。免疫检查点阻断、CAR-T 细胞和双特异性抗体在治疗Richter转化（RT）方面显示出前景，但在慢性淋巴细胞白血病（CLL）中表现出活性降低。这些观察结果表明，除了CLL细胞与转化后的RT细胞之间的内在差异外，这两种实体在肿瘤免疫微环境（TiME）组成和肿瘤-免疫细胞相互作用方面也存在显著差异，而这些差异仍有待充分表征。在本视角中，我们重点介绍近期利用患者来源组织和新型小鼠模型描述CLL和RT中TiME的研究。随后，我们简要概述当前在CLL和RT中采用免疫治疗的临床试验，并对该领域当前面临的挑战和未来研究方向提供展望。
展开英文摘要原文
Immunotherapy has revolutionized the treatment landscape for many cancers, including some B- cell lymphomas. Immune checkpoint blockade, CAR-T cells and bispecific antibodies have shown promise for the treatment of Richter Transformation (RT) but have displayed reduced activity in chronic lymphocytic leukemia (CLL).
These observations suggest that, besides the intrinsic differences between CLL cells and transformed RT cells, there are also marked differences in tumor immune microenvironmental (TiME) composition and tumor-immune cell interactions between these two entities, which remain to be fully characterized. In this perspective, we highlight recent studies describing the TiME in CLL and RT, utilizing both patient-derived tissues and novel mouse models.
We then provide a brief overview of current clinical trials employing immunotherapy in CLL and RT and offer a perspective on current challenges and future research efforts in the field.
论文信息
- 作者
- Vom Stein AF、Nguyen PH、Ten Hacken E
- 第一作者单位
- Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.Germany
- 通讯作者单位
- Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medicine, New York City, NY, United States.United States
- 文献类型
- 综述
- 期刊
- Frontiers in immunology2025
- 原文标识
- PubMed 40510357 · DOI 10.3389/fimmu.2025.1592574
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →